Exploiting the curative potential of adoptive T‐cell therapy for cancer

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628

Mutations of the BRAF gene in human cancer

Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674

Cancer Genome Landscapes

Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia

Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565

Coordinated regulation of myeloid cells by tumours

Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103

Cancer regression in patients after transfer of genetically engineered lymphocytes

Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

Morgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564

The Mutational Landscape of Head and Neck Squamous Cell Carcinoma

Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,541

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417

Epstein–Barr virus: 40 years on

Young, L. S., & Rickinson, A. B. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1452 · Cited by 2,230

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,208

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063

High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993

Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G. R., Margolin, K. A., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,043

A human memory T cell subset with stem cell–like properties

Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974 · cited 3×

Human papillomavirus oncoproteins: pathways to transformation

Moody, C. A., & Laimins, L. A. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2886 · Cited by 1,814

Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766

Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1

Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T., Zhang, J., Wang, J., et al. (2011) · Science · doi:10.1126/science.1206923 · Cited by 1,697

Adoptive immunotherapy for cancer: harnessing the T cell response

Restifo, N. P., Dudley, M. E., & Rosenberg, S. A. (2012) · Nature Reviews Immunology · doi:10.1038/nri3191 · Cited by 1,688

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

Robbins, P. F., Morgan, R. A., Feldman, S. A., Yang, J. C.-H., Sherry, R. M., Dudley, M. E., Wunderlich, J. R., Nahvi, A. V., Helman, L. J., Mackall, C. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2537 · Cited by 1,635

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D., Marić, I., Stetler‐Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2011) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,454

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Johnson, L. A., Morgan, R. A., Dudley, M. E., Cassard, L., Yang, J. C.-H., Hughes, M. S., Kammula, U. S., Royal, R. E., Sherry, R. M., Wunderlich, J. R., et al. (2009) · Blood · doi:10.1182/blood-2009-03-211714 · Cited by 1,421

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337

Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens

Dudley, M. E., Yang, J. C., Sherry, R. M., Hughes, M. S., Royal, R. E., Kammula, U. S., Robbins, P. F., Huang, J., Citrin, D. E., Leitman, S. F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5449 · Cited by 1,334

The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues

Hammarström, S. (1999) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0119 · Cited by 1,303

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L. A., Bagg, A., Carreno, B. M., Cimino, P. J., et al. (2013) · Blood · doi:10.1182/blood-2013-03-490565 · Cited by 1,209

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Morgan, R. A., Chinnasamy, N., Abate‐Daga, D., Gros, A., Robbins, P. F., Zheng, Z., Dudley, M. E., Feldman, S. A., Yang, J. C., Sherry, R. M., et al. (2013) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3182829903 · Cited by 1,181

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L., Miki, T., & Rosenberg, S. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3515 · Cited by 1,093

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

Robbins, P. F., Lu, Y., El‐Gamil, M., Li, Y. F., Gross, C. A., Gartner, J. J., Lin, J., Teer, J. K., Cliften, P. F., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,083

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8 + T cells

Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,073

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis

Parkhurst, M. R., Yang, J. C.-H., Langan, R. C., Dudley, M. E., Nathan, D.-A. N., Feldman, S. A., Davis, J. L., Morgan, R. A., Merino, M. J., Sherry, R. M., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.272 · Cited by 1,025

Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

Overwijk, W. W., Theoret, M. R., Finkelstein, S. E., Surman, D. R., de Jong, L. A., Vyth‐Dreese, F. A., Dellemijn, T. A. M., Antony, P. A., Spiess, P. J., Palmer, D. C., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030590 · Cited by 926

Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience

Lamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915

Tumor-specific Th17-polarized cells eradicate large established melanoma

Muranski, P. J., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 864

Structural alterations of the epidermal growth factor receptor gene in human gliomas.

Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., & Vogelstein, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2965 · Cited by 851

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

Berger, C., Jensen, M. C., Lansdorp, P. M., Gough, M., Elliott, C., & Riddell, S. R. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32103 · Cited by 822

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 807

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

Heslop, H. E., Slobod, K. S., Pulè, M. A., Hale, G. A., Rousseau, A., Smith, C. A., Bollard, C. M., Liu, H., Wu, M.-F., Rochester, R., et al. (2009) · Blood · doi:10.1182/blood-2009-08-239186 · Cited by 783

Why do viruses cause cancer? Highlights of the first century of human tumour virology

Moore, P. S., & Chang, Y. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2961 · Cited by 781

CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

Antony, P. A., Piccirillo, C. A., Akpınarlı, A., Finkelstein, S. E., Speiss, P. J., Surman, D. R., Palmer, D. C., Chan, C., Klebanoff, C. A., Overwijk, W. W., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.2591 · Cited by 754

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

Chang, K., & Pastan, I. H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.136 · Cited by 747

Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742

Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations

González-Galarza, F. F., Christmas, S. E., Middleton, D., & Jones, A. R. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1128 · Cited by 720

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

Lamers, C. H., Sleijfer, S., van Steenbergen, S. C. L., van Elzakker, P., Krimpen, B. A. V., Groot, C., Vulto, A. G., den Bakker, M., Oosterwijk, E., Debets, R., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.17 · Cited by 706

Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells

Cameron, B., Gerry, A. B., Dukes, J. D., Harper, J. V., Kannan, V., Bianchi, F., Grand, F., Brewer, J. E., Gupta, M., Plesa, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006034 · Cited by 703

Expression of Hypoxia-Inducible Cell-Surface Transmembrane Carbonic Anhydrases in Human Cancer

Ivanov, S. V., Liao, S., Ivanova, A. V., Danilkovitch‐Miagkova, A., Tarasova, N. I., Weirich, G., Merrill, M. J., Proescholdt, M. A., Oldfield, E. H., Lee, J., et al. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64038-2 · Cited by 681

B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma

Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M. A., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 667

IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors

Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., Bondanza, A., Bordignon, C., Peccatori, J., Ciceri, F., et al. (2012) · Blood · doi:10.1182/blood-2012-05-431718 · Cited by 660

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

Haque, T., Wilkie, G. M., Jones, M. M., Higgins, C. D., Urquhart, G., Wingate, P. J., Burns, D., McAulay, K. A., Turner, M., Bellamy, C. O. C., et al. (2007) · Blood · doi:10.1182/blood-2006-12-063008 · Cited by 646

Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay, N. E. H., Mosseri, V., Laccourreye, O., Bruneval, P., Fridman, W. H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1886 · Cited by 630

Paths to stemness: building the ultimate antitumour T cell

Gattinoni, L., Klebanoff, C. A., & Restifo, N. P. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3322 · Cited by 616

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.

Bakker, A. B. H., Schreurs, M. W. J., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., & Figdor, C. G. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.179.3.1005 · Cited by 589

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling

Paulos, C. M., Wrzesinski, C., Kaiser, Hinrichs, C. S., Chieppa, M., Cassard, L., Palmer, D. C., Boni, A., Muranski, P., Yu, Z., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32205 · Cited by 586 · cited 1×

Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

Haso, W. M., Lee, D. W., Shah, N. N., Stetler‐Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2012) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 579

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

Lee, W., Jiang, Z., Liu, J., Haverty, P. M., Guan, Y., Stinson, J., Yue, P., Zhang, Y., Pant, K. P., Bhatt, D., et al. (2010) · Nature · doi:10.1038/nature09004 · Cited by 492

Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting

Sok, J. C., Coppelli, F. M., Thomas, S. M., Lango, M. N., Xi, S., Hunt, J. L., Freilino, M. L., Graner, M. W., Wikstrand, C. J., Bigner, D. D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0913 · Cited by 488

Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2

Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 486

Exome sequencing identifies GRIN2A as frequently mutated in melanoma

Program, N. C. S., Wei, X., Walia, V., Lin, J., Teer, J. K., Prickett, T. D., Gartner, J. J., Davis, S. R., Stemke‐Hale, K., Davies, M. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.810 · Cited by 471

High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma

Klapper, J. A., Downey, S. G., Smith, F. O., Yang, J. C., Hughes, M. S., Kammula, U. S., Sherry, R. M., Royal, R. E., Steinberg, S. M., & Rosenberg, S. A. (2008) · Cancer · doi:10.1002/cncr.23552 · Cited by 433

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

Radvanyi, L., Bernatchez, C., Zhang, M.-Y., Fox, P., Miller, P. W., Chacon, J. A., Wu, R. C., Lizée, G., Mahoney, S. L., Alvarado, G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1177 · Cited by 423

Do No Harm

Jonsen, A. R. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-88-6-827 · Cited by 414

High number of intraepithelial cd8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer

Piersma, S. J., Jordanova, E. S., van Poelgeest, M. I. E., Kwappenberg, K. M. C., van der Hulst, J. M., Drijfhout, J. W., Melief, C. J. M., Kenter, G. G., Fleuren, G. J., Offringa, R., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3388 · Cited by 414

Adoptively transferred effector cells derived from naïve rather than central memory CD8+ T cells mediate superior antitumor immunity

Hinrichs, C., Borman, Z. A., Cassard, L., Gattinoni, L., Spolski, R., Yu, Z.-Y., Sanchez-Perez, L., Muranski, P., Kern, S., Logun, C., et al. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0907448106 · Cited by 407

Cytotoxic T Lymphocyte Therapy for Epstein-Barr Virus+ Hodgkin's Disease

Bollard, C. M., Aguilar, L. K., Straathof, K. C. M., Gahn, B., Huls, M. H., Rousseau, A., Sixbey, J. W., Gresik, M. V., Carrum, G., Hudson, M. M., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040890 · Cited by 387

Single and Dual Amino Acid Substitutions in TCR CDRs Can Enhance Antigen-Specific T Cell Functions

Robbins, P. F., Li, Y. F., El‐Gamil, M., Zhao, Y., Wargo, J. A., Zheng, Z., Xu, H., Morgan, R. A., Feldman, S. A., Johnson, L. A., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.9.6116 · Cited by 385

Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma.

Humphrey, P. A., Wong, A. J., Vogelstein, B., Zalutsky, M. R., Fuller, G. N., Archer, G. E., Friedman, H. S., Kwatra, M. M., Bigner, S. H., & Bigner, D. D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4207 · Cited by 382

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4

Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352

Genome-wide analysis of cancer/testis gene expression

Hofmann, O., Caballero, O. L., Stevenson, B. J., Chen, Y., Cohen, T., Chua, R. A., Maher, C. A., Panji, S., Schaefer, U., Kruger, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810777105 · Cited by 342

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors

Kerkar, S. P., Goldszmid, R. S., Muranski, P. J., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 340

Telomere Length of Transferred Lymphocytes Correlates with In Vivo Persistence and Tumor Regression in Melanoma Patients Receiving Cell Transfer Therapy

Zhou, J., Shen, X., Huang, J., Hodes, R. J., Rosenberg, S. A., & Robbins, P. F. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.10.7046 · Cited by 336

A live-cell assay to detect antigen-specific CD4+ T cells with diverse cytokine profiles

Chattopadhyay, P. K., Yu, J., & Roederer, M. (2005) · Nature Medicine · doi:10.1038/nm1293 · Cited by 321

Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma

Morgan, R. A., Johnson, L. A., Davis, J. L., Zheng, Z., Woolard, K., Reap, E. A., Feldman, S. A., Chinnasamy, N., Kuan, C.-T., Song, H., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.041 · Cited by 310

Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy

Hinrichs, C. S., Borman, Z. A., Gattinoni, L., Yu, Z., Burns, W. R., Huang, J., Klebanoff, C. A., Johnson, L. A., Kerkar, S. P., Yang, S., et al. (2010) · Blood · doi:10.1182/blood-2010-05-286286 · Cited by 309

Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas

Marshall, J. L., Gulley, J. L., Arlen, P. M., Beetham, P. K., Tsang, K.-Y., Slack, R. S., Hodge, J. W., DOREN, S., Grosenbach, D. W., Hwang, J. J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.206 · Cited by 298

Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes

Comoli, P., Pedrazzoli, P., Maccario, R., Basso, S., Carminati, O., Labirio, M., Schiavo, R., Secondino, S., Frasson, C., Perotti, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.6195 · Cited by 288

Cancer immunology—analysis of host and tumor factors for personalized medicine

Ogino, S., Galon, J., Fuchs, C. S., & Dranoff, G. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.122 · Cited by 287

Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells

Wrzesinski, C., Paulos, C. M., Kaiser, A., Muranski, P. J., Palmer, D. C., Gattinoni, L., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181b88ffc · Cited by 284

Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion.

Lal, A., Glazer, C. A., Martinson, H. M., Friedman, H. S., Archer, G. E., Sampson, J. H., & Riggins, G. J. (2002) · PubMed · Cited by 278

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes.

Wang, R. F., Robbins, P. F., Kawakami, Y., Kang, X. Q., & Rosenberg, S. A. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.181.2.799 · Cited by 270

The Inducible Costimulator (ICOS) Is Critical for the Development of Human T H 17 Cells

Paulos, C. M., Carpenito, C., Plesa, G., Suhoski, M. M., Varela‐Rohena, A., Golovina, T. N., Carroll, R. G., Riley, J. L., & June, C. H. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000448 · Cited by 266

Raising the Bar: The Curative Potential of Human Cancer Immunotherapy

Rosenberg, S. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003634 · Cited by 249

T-cell therapy in the treatment of post-transplant lymphoproliferative disease

Bollard, C. M., Rooney, C. M., & Heslop, H. E. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.111 · Cited by 240

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

Smith, F. O., Downey, S. G., Klapper, J. A., Yang, J. C.-H., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Restifo, N. P., Levy, C. L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0116 · Cited by 239

Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma

Dudley, M. E., Gross, C. A., Somerville, R. P. T., Hong, Y. K., Schaub, N. P., Rosati, S. F., White, D. E., Nathan, D., Restifo, N. P., Steinberg, S. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.6441 · Cited by 236

Adoptive Transfer of EBV-specific T Cells Results in Sustained Clinical Responses in Patients With Locoregional Nasopharyngeal Carcinoma

Louis, C. U., Straathof, K. C. M., Bollard, C. M., Ennamuri, S., Gerken, C. P., Lopez, T., Huls, M. H., Sheehan, A. M., Wu, M.-F., Liu, H., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f3cbf4 · Cited by 230

Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells

Inozume, T., Hanada, K., Wang, Q. J., Ahmadzadeh, M., Wunderlich, J. R., Rosenberg, S. A., & Yang, J. C.-H. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181fad2b0 · Cited by 230

Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma

Gulley, J. L., Arlen, P. M., Tsang, K.-Y., Yokokawa, J., Palena, C., Poole, D. J., Remondo, C., Cereda, V., Jones, J. L., Pazdur, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0126 · Cited by 228

Type 17 CD8+ T cells display enhanced antitumor immunity

Hinrichs, C. S., Kaiser, A., Paulos, C. M., Cassard, L., Sanchez-Perez, L. A., Heemskerk, B., Wrzesinski, C., Borman, Z. A., Muranski, P. J., & Restifo, N. P. (2009) · Blood · doi:10.1182/blood-2009-02-203935 · Cited by 226

Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer

Yao, X., Ahmadzadeh, M., Lu, Y., Liewehr, D. J., Dudley, M. E., Liu, F., Schrump, D. S., Steinberg, S. M., Rosenberg, S. A., & Robbins, P. F. (2012) · Blood · doi:10.1182/blood-2011-10-386482 · Cited by 207

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells

Wrzesinski, C., Paulos, C. M., Gattinoni, L., Palmer, D. C., Kaiser, A., Yu, Z., Rosenberg, S. A., & Restifo, N. P. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30414 · Cited by 203

Live-cell assay to detect antigen-specific CD4+ T-cell responses by CD154 expression

Chattopadhyay, P. K., Yu, J., & Roederer, M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.1 · Cited by 201

Carbonic Anhydrase IX Is Not an Independent Predictor of Outcome for Patients With Clear Cell Renal Cell Carcinoma

Leibovich, B. C., Sheinin, Y. M., Lohse, C. M., Thompson, R. H., Cheville, J. C., Závada, J., & Kwon, E. D. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1087 · Cited by 197

Analysis of the genome to personalize therapy for melanoma

Davies, M. A., & Samuels, Y. (2010) · Oncogene · doi:10.1038/onc.2010.323 · Cited by 190

Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII)

Chu, C. T., Everiss, K. D., Wikstrand, C. J., Batra, S. K., Kung, H.-J., & Bigner, D. D. (1997) · Biochemical Journal · doi:10.1042/bj3240855 · Cited by 184

TIL therapy broadens the tumor-reactive CD8+T cell compartment in melanoma patients

Kvistborg, P., Shu, C. J., Heemskerk, B., Fankhauser, M., Thrue, C. A., Toebes, M., van Rooij, N., Linnemann, C., van Buuren, M. M., Urbanus, J. H. M., et al. (2012) · OncoImmunology · doi:10.4161/onci.18851 · Cited by 178

Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.

Seung, L. P., Rowley, D. A., Dubey, P., & Schreiber, H. W. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6254 · Cited by 176

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

Ellebæk, E., Iversen, T. Z., Junker, N., Donia, M., Engell-Noerregaard, L., Met, Ö., Hölmich, L. R., Andersen, R. S., Hadrup, S. R., Andersen, M. H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-169 · Cited by 172

Tumoral and Immunologic Response After Vaccination of Melanoma Patients With an ALVAC Virus Encoding MAGE Antigens Recognized by T Cells

van Baren, N., Bonnet, M.-C., Dréno, B., Khammari, A., Dorval, T., Piperno-Neumann, S., Líénard, D., Speiser, D. E., Marchand, M., Brichard, V. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.375 · Cited by 172

Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy

Itzhaki, O., Hovav, E., Ziporen, Y., Levy, D., Kubi, A., Zikich, D., Hershkovitz, L., Treves, A. J., Shalmon, B., Zippel, D. B., et al. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318209c94c · Cited by 170

Use of tumour-responsive T cells as cancer treatment

Disis, M. L., Bernhard, H., & Jaffee, E. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60404-9 · Cited by 167

Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma

Palavalli, L. H., Prickett, T. D., Wunderlich, J. R., Wei, X., Burrell, A. S., Porter-Gill, P. A., Davis, S. R., Wang, C., Cronin, J. C., Agrawal, N., et al. (2009) · Nature Genetics · doi:10.1038/ng.340 · Cited by 162

Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming

Atanackovic, D., Altorki, N. K., Cao, Y., Ritter, E., Ferrara, C. A., Ritter, G., Hoffman, E. W., Bokemeyer, C., Old, L. J., & Gnjatic, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707140104 · Cited by 156

Modulation by IL-2 of CD70 and CD27 Expression on CD8+ T Cells: Importance for the Therapeutic Effectiveness of Cell Transfer Immunotherapy

Huang, J., Kerstann, K. W., Ahmadzadeh, M., Li, Y. F., El‐Gamil, M., Rosenberg, S. A., & Robbins, P. F. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.12.7726 · Cited by 154

Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression

Lu, Y., Yao, X., Li, Y. F., El‐Gamil, M., Dudley, M. E., Yang, J. C.-H., Almeida, J. R., Douek, D. C., Samuels, Y., Rosenberg, S. A., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202830 · Cited by 153

Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma

Prickett, T. D., Wei, X., Cárdenas-Navia, I., Teer, J. K., Lin, J., Walia, V., Gartner, J. J., Jiang, J., Cherukuri, P. F., Molinolo, A. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.950 · Cited by 150

FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions

Ahmadzadeh, M., Felipe-Silva, A., Heemskerk, B., Powell, D. J., Wunderlich, J. R., Merino, M. J., & Rosenberg, S. A. (2008) · Blood · doi:10.1182/blood-2008-06-163048 · Cited by 143

Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity

Palmer, D. C., Chan, C., Gattinoni, L., Wrzesinski, C., Paulos, C. M., Hinrichs, C. S., Powell, D. J., Klebanoff, C. A., Finkelstein, S. E., Fariss, R. N., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710929105 · Cited by 130

Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells

Parkhurst, M. R., Joo, J. S., Riley, J. P., Yu, Z., Li, Y., Robbins, P. F., & Rosenberg, S. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1638 · Cited by 122

Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response

Rosenberg, S. A., Yang, J., White, D. E., & Steinberg, S. M. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68669-7 · Cited by 116

Constitutive EGFR signaling confers a motile phenotype to neural stem cells

Boockvar, J. A., Kapitonov, D., Kapoor, G. S., Schouten, J. W., Counelis, G. J., Bögler, O., Snyder, E. Y., McIntosh, T. K., & O’Rourke, D. M. (2003) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2003.09.011 · Cited by 115

Epstein–Barr virus and carcinogenesis: beyond Burkitt's lymphoma

Shah, K. S., & Young, L. S. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2009.03033.x · Cited by 115

Tumour infiltrating lymphocytes in squamous cell carcinoma of the oro- and hypopharynx: Prognostic impact may depend on type of treatment and stage of disease

Distel, L. V., Fickenscher, R., Dietel, K., Hung, A., Iro, H., Zenk, J., Nkenke, E., Büttner, M., Niedobitek, G., & Grabenbauer, G. G. (2009) · Oral Oncology · doi:10.1016/j.oraloncology.2009.05.640 · Cited by 110

Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?

Fojo, T., & Parkinson, D. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1277 · Cited by 110

Phenotype and Function of T Cells Infiltrating Visceral Metastases from Gastrointestinal Cancers and Melanoma: Implications for Adoptive Cell Transfer Therapy

Turcotte, S., Gros, A., Hogan, K., Tran, E., Hinrichs, C. S., Wunderlich, J. R., Dudley, M. E., & Rosenberg, S. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300538 · Cited by 107

Expression of CD27 on Murine Hematopoietic Stem and Progenitor Cells

Wiesmann, A., Phillips, R. L., Mojica-Henshaw, M. P., Pierce, L., Searles, A. E., Spangrude, G. J., & Lemischka, I. R. (2000) · Immunity · doi:10.1016/s1074-7613(00)80172-7 · Cited by 103

Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development

Kelly, R. J., Sharon, E., Pastan, I. H., & Hassan, R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0454 · Cited by 102

Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor

Ullenhag, G. J., Frödin, J., Jeddi‐Tehrani, M., Strigård, K., Eriksson, E., Samanci, A., Choudhury, A., Nilsson, B., Rossmann, E. D., Mosolits, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0706 · Cited by 92

Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma

Gros, A., Turcotte, S., Wunderlich, J. R., Ahmadzadeh, M., Dudley, M. E., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1108 · Cited by 86

Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA‐DQ and –DP as a restriction element

Piersma, S. J., Welters, M. J. P., van der Hulst, J. M., Kloth, J. N., Kwappenberg, K. M. C., Trimbos, B. J. B. M. Z., Melief, C. J. M., Hellebrekers, B. W. J., Fleuren, G. J., Kenter, G. G., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.23162 · Cited by 85

An Unexpectedly Large Polyclonal Repertoire of HPV-Specific T Cells Is Poised for Action in Patients with Cervical Cancer

van Steenwijk, P. J. D. V., Heusinkveld, M., Ramwadhdoebé, T. H., Löwik, M. J. G., van der Hulst, J. M., Goedemans, R., Piersma, S. J., Kenter, G. G., & van der Burg, S. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4299 · Cited by 84

Infiltration by immunocompetent cells in early stage invasive carcinoma of the uterine cervix: a prognostic study

Bethwaite, P. B., Holloway, L., Thornton, A., & Delahunt, B. (1996) · Pathology · doi:10.1080/00313029600169274 · Cited by 82

A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

Wagner, H., Bollard, C. M., Vigouroux, S., Huls, M. H., Anderson, R. W., Prentice, H. G., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700664 · Cited by 76

Immune activation modulates hematopoiesis through interactions between CD27 and CD70

Nolte, M. A., Arens, R., van Os, R. P., van Oosterwijk, M. F., Hooibrink, B., van Lier, R. A. W., & van Oers, M. H. J. (2005) · Nature Immunology · doi:10.1038/ni1174 · Cited by 74

Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas

Kerkar, S. P., Leonardi, A. J., van Panhuys, N., Zhang, L., Yu, Z., Crompton, J. G., Pan, J. H., Palmer, D. C., Morgan, R. A., Rosenberg, S. A., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.58 · Cited by 64

Mutational and Functional Analysis Reveals ADAMTS18 Metalloproteinase as a Novel Driver in Melanoma

Wei, X., Prickett, T. D., Viloria, C. G., Molinolo, A., Lin, J., Cárdenas-Navia, I., Cruz, P., Rosenberg, S. A., Davies, M. A., Gershenwald, J. E., et al. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0262 · Cited by 56

Tumor-infiltrating lymphocytes from nonrenal urological malignancies

Haas, G. P., Solomon, D., & Rosenberg, S. A. (1990) · Cancer Immunology Immunotherapy · doi:10.1007/bf01786883 · Cited by 51

The development of new cancer therapies based on the molecular identification of cancer regression antigens.

Rosenberg, S. A. (2006) · PubMed · Cited by 44

Delving into somatic variation in sporadic melanoma

Walia, V., Mu, E. W., Lin, J., & Samuels, Y. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00976.x · Cited by 41

Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma

Gartner, J. J., Davis, S. R., Wei, X., Lin, J., Trivedi, N. S., Teer, J. K., Program, N. C. S., Meltzer, P. S., Rosenberg, S. A., & Samuels, Y. (2012) · BMC Genomics · doi:10.1186/1471-2164-13-505 · Cited by 37

Evaluation of γ-Retroviral Vectors That Mediate the Inducible Expression of IL-12 for Clinical Application

Zhang, L., Feldman, S. A., Zheng, Z., Chinnasamy, N., Xu, H., Nahvi, A. V., Dudley, M. E., Rosenberg, S. A., & Morgan, R. A. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31825898e8 · Cited by 32

with Chemotherapy-Refractory Acute Lymphoblastic Leukemia CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults

Brentjens, R. J. (2013) · Cited by 29

Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma and Normal Tissues: Experiences From (Radio) Immunotherapy

Brouwers, A. H., Mulders, P. F. A., & Oyen, W. J. G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.6073 · Cited by 12

Do no harm

(2013) · Nature Biotechnology · doi:10.1038/nbt.2587 · Cited by 7

Untitled work

Hsing (1996) · doi:10.1002/(sici)1097-0215(19960208)65:4 · Cited by 1

Neoantigens in cancer immunotherapy

Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783

Molecular and genetic properties of tumors associated with local immune cytolytic activity

Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825

Chimeric antigen receptor T-cell therapy—assessment and management of toxicities

Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438

CD4+ T cell help in cancer immunology and immunotherapy

Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585

Cancer immunotherapy: the beginning of the end of cancer?

Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,231

Adoptive Cell Therapy for Metastatic Melanoma

Merhavi-Shoham, E., Itzhaki, O., Markel, G., Schachter, J., & Besser, M. J. (2017) · The Cancer Journal · doi:10.1097/ppo.0000000000000240 · Cited by 62

Adoptive T-Cell Therapy for Cancer

Yang, J. C.-H., & Rosenberg, S. A. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.006 · Cited by 208

Adoptive T-cell Transfer in Melanoma

Itzhaki, O., Levy, D., Zikich, D., Treves, A. J., Markel, G., Schachter, J., & Besser, M. J. (2012) · Immunotherapy · doi:10.2217/imt.12.143 · Cited by 24

Adoptive Cell Transfer for Patients with Metastatic Melanoma: The Potential and Promise of Cancer Immunotherapy

Phan, G. Q., & Rosenberg, S. A. (2013) · Cancer Control · doi:10.1177/107327481302000406 · Cited by 107

Abstract IA19: Curative potential of T-cell immunotherapy for cancer

Rosenberg, S. A. (2015) · Cancer Immunology Research · doi:10.1158/2326-6074.tumimm14-ia19